Gilead Sciences stock holds near highs as Q2 2026 EPS beats and new ex-dividend date nears
Published on 09/10/2026 at 11:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences, Inc. stock (ISIN US3755581036) ended trading on Nasdaq at USD 145.65 on September 9, 2026, only modestly below its recent 52-week high, after the company reported a stronger-than-expected Q2 2026 earnings performance with an EPS that topped consensus by USD 0.50 according to MarketBeat.
Q2 2026 earnings beat supports valuation
According to MarketBeat, Gilead Sciences posted Q2 2026 revenue of USD 7.80 billion, coming in above the revenue estimate of USD 7.40 billion for the quarter.
The same overview from MarketBeat shows that Gilead Sciences reported Q2 2026 EPS of negative USD 6.75, which was USD 0.50 better than the consensus estimate of negative USD 7.25.
This combination of a top-line beat and an EPS result above expectations in Q2 2026 gives investors more confidence that the company can fund its HIV and oncology pipeline while maintaining its dividend policy.
Dividend and ex-dividend date in September 2026
Dividend continuity remains an important part of the Gilead Sciences equity story for income-oriented investors.
According to the dividend section in the biotech comparison from MarketBeat, Gilead Sciences announced a quarterly dividend of USD 0.82 per share, corresponding to a yield of about 2.43 percent, with an ex-dividend date on September 15, 2026 and a payable date on September 29, 2026.
These concrete dates in September 2026 give short-term investors a clear timeline for dividend capture strategies, while longer-term holders see the payout as a signal of confidence following the Q2 2026 earnings beat.
Pipeline and conference commentary add strategic context
Beyond numbers, the latest commentary around Gilead Sciences highlights how the company is balancing its established HIV franchise with newer growth avenues in oncology and inflammation.
As Investing.com reported on September 9, 2026, Gilead Sciences used its appearance at the Wells Fargo 21st Annual Healthcare Conference to outline a broader growth plan that still leans on its HIV franchise but increasingly targets oncology and inflammation as additional pillars.
The analysis on Gilead Sciences from Yahoo Finance on September 10, 2026 highlights that HIV remains a core growth area and notes that Gilead is expanding prevention options across daily, weekly and long-acting dosing formats, including a regulatory decision on weekly oral lenacapavir expected in the first quarter of next year.
This combination of a Q2 2026 earnings beat, a steady dividend and upcoming regulatory milestones in HIV and oncology shapes how the market values Gilead Sciences stock in the second half of 2026.
Stock price near recent highs on Nasdaq
Per the biotech stock overview from MarketBeat, Gilead Sciences is listed on Nasdaq under the ticker GILD and closed at USD 145.65 on September 9, 2026, down 0.68 percent for the session.
The same snapshot from MarketBeat shows a 52-week high and low range for Gilead Sciences stock around the current price level, with a closing quote of USD 145.65 that sits close to the upper end of that band, and a market capitalization in the large-cap biotech bracket as of September 9, 2026.
Trading volume on that day was consistent with recent averages, indicating that the Q2 2026 earnings beat and upcoming ex-dividend date are being digested without extreme volatility.
Gilead Sciences stock - key data
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Trading venue: Nasdaq
- Price (as of September 9, 2026, 16:00): 145.65 USD
- Market capitalization: large-cap biotech, as of September 9, 2026
- Sector / Industry: Biotechnology / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: November 2, 2026
